NASDAQ:MEDP - Medpace Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $60.47 +1.51 (+2.56 %) (As of 01/15/2019 04:00 PM ET)Previous Close$58.96Today's Range$59.15 - $61.0152-Week Range$31.75 - $65.09Volume618,200 shsAverage Volume757,740 shsMarket Capitalization$2.14 billionP/E Ratio39.78Dividend YieldN/ABeta1.61 ProfileDiscussionAnalyst RatingsChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Medpace Holdings, Inc., a clinical contract research organization, provides scientifically-driven outsourced clinical development services to the biotechnology, pharmaceutical, and medical device industries worldwide. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in a range of therapeutic areas. Its clinical development services include medical affairs, clinical trial management, feasibility and start-up study, clinical monitoring, global regulatory affairs, medical writing, biometrics, pharmacovigilance, core laboratory, and quality assurance. Medpace Holdings, Inc. was founded in 1992 and is headquartered in Cincinnati, Ohio. Receive MEDP News and Ratings via Email Sign-up to receive the latest news and ratings for MEDP and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Commercial physical research Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:MEDP Previous Symbol CUSIPN/A Webwww.medpace.com Phone513-579-9911Debt Debt-to-Equity Ratio0.25 Current Ratio0.66 Quick Ratio0.66Price-To-Earnings Trailing P/E Ratio39.78 Forward P/E Ratio24.09 P/E Growth1.3 Sales & Book Value Annual Sales$436.15 million Price / Sales4.94 Cash Flow$2.6441 per share Price / Cash Flow22.87 Book Value$13.40 per share Price / Book4.51Profitability EPS (Most Recent Fiscal Year)$1.52 Net Income$39.12 million Net Margins10.84% Return on Equity15.86% Return on Assets8.74%Miscellaneous Employees2,500 Outstanding Shares35,600,000Market Cap$2.14 billion OptionableOptionable Medpace (NASDAQ:MEDP) Frequently Asked Questions What is Medpace's stock symbol? Medpace trades on the NASDAQ under the ticker symbol "MEDP." How were Medpace's earnings last quarter? Medpace Holdings Inc (NASDAQ:MEDP) posted its quarterly earnings results on Thursday, November, 1st. The company reported $0.67 EPS for the quarter, topping the consensus estimate of $0.63 by $0.04. The company earned $179 million during the quarter, compared to analysts' expectations of $175.07 million. Medpace had a net margin of 10.84% and a return on equity of 15.86%. The firm's revenue was up 44.4% on a year-over-year basis. During the same quarter in the previous year, the business posted $0.40 EPS. View Medpace's Earnings History. When is Medpace's next earnings date? Medpace is scheduled to release their next quarterly earnings announcement on Monday, February 25th 2019. View Earnings Estimates for Medpace. What guidance has Medpace issued on next quarter's earnings? Medpace updated its FY18 earnings guidance on Monday, October, 29th. The company provided earnings per share guidance of $2.76-2.82 for the period, compared to the Thomson Reuters consensus estimate of $2.48. Medpace also updated its FY 2018 guidance to $2.76-2.82 EPS. What price target have analysts set for MEDP? 7 brokers have issued 12-month target prices for Medpace's stock. Their forecasts range from $35.00 to $63.00. On average, they expect Medpace's share price to reach $42.8333 in the next twelve months. This suggests that the stock has a possible downside of 29.2%. View Analyst Price Targets for Medpace. What is the consensus analysts' recommendation for Medpace? 7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Medpace in the last year. There are currently 4 hold ratings and 3 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Medpace. Has Medpace been receiving favorable news coverage? News headlines about MEDP stock have been trending somewhat positive this week, according to InfoTrie Sentiment Analysis. The research firm identifies positive and negative news coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. Medpace earned a coverage optimism score of 1.9 on InfoTrie's scale. They also gave media coverage about the company a news buzz of 10.0 out of 10, indicating that recent news coverage is extremely likely to have an impact on the stock's share price in the near future. Are investors shorting Medpace? Medpace saw a increase in short interest in December. As of December 31st, there was short interest totalling 2,286,982 shares, an increase of 63.3% from the December 14th total of 1,400,643 shares. Based on an average daily trading volume, of 1,303,229 shares, the days-to-cover ratio is presently 1.8 days. Approximately 8.5% of the company's stock are sold short. View Medpace's Current Options Chain. Who are some of Medpace's key competitors? Some companies that are related to Medpace include Icon (ICLR), Exelixis (EXEL), PRA Health Sciences (PRAH), Charles River Laboratories Intl. (CRL), Syneos Health (SYNH), BTG (BTGGF), Sorrento Therapeutics (SRNE), Pieris Pharmaceuticals (PIRS), Luna Innovations (LUNA), Anavex Life Sciences (AVXL), Senomyx (SNMX), Dyadic International (DYAI), BIOQUAL (BIOQ), HedgePath Pharmaceuticals (HPPI) and Vitality Biopharma (VBIO). Who are Medpace's key executives? Medpace's management team includes the folowing people: Dr. August James Troendle, Chairman, Pres & CEO (Age 62)Mr. Jesse J. Geiger, CFO & Chief Operating Officer of Laboratory Operations (Age 44)Ms. Susan E. Burwig, Exec. VP of Operations (Age 55)Mr. Stephen P. Ewald, Gen. Counsel & Corp. Sec. (Age 49)Mr. Todd Meyers, VP of Bus. Devel. & Marketing When did Medpace IPO? (MEDP) raised $150 million in an initial public offering (IPO) on Thursday, August 11th 2016. The company issued 7,000,000 shares at $20.00-$23.00 per share. Jefferies, Credit Suisse, UBS Investment Bank and Wells Fargo Securities served as the underwriters for the IPO and Baird and William Blair were co-managers. Who are Medpace's major shareholders? Medpace's stock is owned by many different of retail and institutional investors. Top institutional investors include Scout Investments Inc. (0.17%), Navellier & Associates Inc (0.01%) and State of Alaska Department of Revenue (0.00%). Company insiders that own Medpace stock include August J Troendle, Jesse J Geiger, Medpace Investors, Llc and Medpace Limited Partnership. View Institutional Ownership Trends for Medpace. Which institutional investors are buying Medpace stock? MEDP stock was bought by a variety of institutional investors in the last quarter, including Scout Investments Inc., Navellier & Associates Inc and State of Alaska Department of Revenue. View Insider Buying and Selling for Medpace. How do I buy shares of Medpace? Shares of MEDP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Medpace's stock price today? One share of MEDP stock can currently be purchased for approximately $60.47. How big of a company is Medpace? Medpace has a market capitalization of $2.14 billion and generates $436.15 million in revenue each year. The company earns $39.12 million in net income (profit) each year or $1.52 on an earnings per share basis. Medpace employs 2,500 workers across the globe. What is Medpace's official website? The official website for Medpace is http://www.medpace.com. How can I contact Medpace? Medpace's mailing address is 5375 MEDPACE WAY, CINCINNATI OH, 45227. The company can be reached via phone at 513-579-9911 or via email at [email protected] MarketBeat Community Rating for Medpace (NASDAQ MEDP)Community Ranking: 2.6 out of 5 ( )Outperform Votes: 217 (Vote Outperform)Underperform Votes: 196 (Vote Underperform)Total Votes: 413MarketBeat's community ratings are surveys of what our community members think about Medpace and other stocks. Vote "Outperform" if you believe MEDP will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MEDP will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 1/15/2019 by MarketBeat.com StaffFeatured Article: What is the Ex-Dividend Date in Investing?